Amgen EVP reports tax-withholding of 6,022 shares

AMGEN INC executive David M. Reese reported a compensation-related share disposition tied to tax obligations.

Accepted by SEC EDGAR 03/18/2026 - 08:38 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

AMGEN INC executive David M. Reese reported a compensation-related share disposition tied to tax obligations. On March 16, 2026, 6,022 shares of Amgen common stock were delivered at $366.21 per share to satisfy tax liability or exercise costs, a transaction coded as tax-withholding. Following this event, Reese directly held 41,787 Amgen shares. A portion of his position also reflects dividend equivalents credited to unvested restricted stock units that will be paid in shares as they vest.

Insider Trade Summary

Exercise Price or Tax Liability: 6,022 shares

Exercise Price or Tax Liability 1 txn

Insider REESE DAVID M

Role EVP & Chief Technology Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	6,022	$366.21	$2.21M

Holdings After Transaction: Common Stock — 41,787 shares (Direct)

Holdings Before and After: Common Stock, 47,809 to 41,787 shares (Direct)

Footnotes (1)

1. F1. These shares include 744 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Amgen (AMGN) EVP David M. Reese report?

David M. Reese reported a tax-related share disposition of 6,022 Amgen common shares on March 16, 2026. The Form 4 shows these shares were delivered to cover a tax liability or exercise price, not as an open-market sale.

Was David M. Reese’s Amgen (AMGN) Form 4 transaction an open-market sale?

No, the transaction was coded “F”, meaning tax-withholding or payment of an exercise price using shares. This indicates the shares were used to satisfy obligations related to equity awards, rather than being sold in the open market.

How many Amgen (AMGN) shares does David M. Reese hold after this Form 4?

After the tax-withholding disposition of 6,022 shares, David M. Reese directly holds 41,787 shares of Amgen common stock. This figure reflects his remaining direct ownership following the reported transaction on March 16, 2026.

At what price were the Amgen (AMGN) shares valued in Reese’s tax-withholding transaction?

The 6,022 Amgen shares delivered for tax or exercise obligations were valued at $366.21 per share. This price is used in the Form 4 to calculate the total value of the tax-withholding disposition reported for March 16, 2026.

What are dividend equivalents (DEs) mentioned in David M. Reese’s Amgen (AMGN) filing?

Dividend equivalents are credits linked to unvested restricted stock units that mirror dividends on Amgen shares. The filing notes 744 DEs, which will be paid out in Amgen common stock as the related RSUs vest, plus cash for any fractional amounts.

Which equity plan governs David M. Reese’s Amgen (AMGN) dividend equivalents?

The dividend equivalents are granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. They are tied to unvested restricted stock units and are paid out in Amgen common shares according to the awards’ vesting schedules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REESE DAVID M

(Last) (First) (Middle)

ONE AMGEN CENTER

DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		F		6,022	D	$366.21	41,787(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 744 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ David M. Reese	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)